Tag: release

TORONTO, June 19, 2026 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (“BlackRock”) (NYSE:BLK), today announced updated investment risk ratings of the iShares ETFs listed below, effective as of June 19, 2026:

TORONTO, 19 juin 2026 (GLOBE NEWSWIRE) -- Gestion d’actifs BlackRock Canada Limitée (« BlackRock Canada »), filiale indirecte en propriété exclusive de BlackRock, Inc. (« BlackRock ») (NYSE : BLK), a annoncé aujourd’hui avoir mis à jour les niveaux de risque de placement des FNB iShares énumérés ci-après, avec prise d’effet en date du 19 juin 2026 :

New investor signal-intelligence platform reads social, forum, and news chatter across thousands of conversations — and surfaces the tickers the crowd is piling into, with the sentiment and catalysts behind them. Free to start.

The new storefront expands the company's safe and vault openings, commercial door and frame replacement, access control, and automotive key services from Montrose into the greater Grand Junction and Mesa County market.

Emily Sanford Fisher discusses how data centers, electrification, and infrastructure expansion are driving renewed electricity demand growth across the United States.

CALGARY, Alberta, June 19, 2026 (GLOBE NEWSWIRE) -- Condor Energies Inc. (TSX: CDR), a Canadian based energy company, is pleased to announce that the following five director nominees were elected at the Annual Meeting of Shareholders held on June 19, 2026:

ניו יורק, June 20, 2026 (GLOBE NEWSWIRE) --

מדוע: משרד רוזן עורכי דין (Rosen Law Firm), משרד עורכי דין בינלאומי העוסק בזכויות משקיעים, מזכיר לרוכשי ניירות הערך של Lucid Group, Inc. (נאסד"ק: LCID) בין התאריכים 25 בפברואר 2026 עד 13 באפריל 2026, שני התאריכים כוללים ("תקופת התביעה הייצוגית"), את המועד האחרון החשוב של 28 ביולי 2026 להגשת תביעה ייצוגית בניירות ערך.

SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 18, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 140,860 shares of Iovance’s common stock to twenty-seven new, non-executive employees.